Compare Davita Inc (DVA) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Ryanair Holdings plc — how do they compare? Davita Inc trades at $230.55 (market cap $14.92B), while Ryanair Holdings plc trades at $64.3 (market cap $31.19B). The key difference: Ryanair Holdings plc is far larger — about 2.1× Davita Inc's market cap, and Ryanair Holdings plc pays a 1.54% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | RYAAY | |
|---|---|---|
Market Cap | $14.92B | $31.19B |
Sector | Health | Industrials |
52-Week High | $235.71 | $73.82 |
52-Week Low | $103.87 | $53.24 |
Enterprise Value | $27.47B | $28.85B |
Dividend Yield | — | 1.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
RYAAY trades at $63.91, down 1.14% today, with a bullish technical signal from moving averages and neutral oscillators. The company shows strong profitability with a 13.98% net income margin and 25.37% ROE, supported by consistent earnings beats in recent quarters. Recent news includes a window incident investigation and CEO contract extension, while passenger traffic grew 7% year-over-year in June 2026 (Zacks Investment Research, 2026-07-02).
The outlook remains positive with analyst consensus at 62.5% buy ratings, though risks include rising fuel costs and regulatory scrutiny. Valuation appears reasonable with a P/E of 13.74 and EV/EBITDA of 6.57, suggesting potential upside if travel demand sustains. Near-term focus is on Q2 2026 earnings against expectations of $1.37 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
